Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Partnerships 21
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Licensing Agreements 23
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Equity Offering 29
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc – Key Competitors 39
Atara Biotherapeutics Inc – Key Employees 40
Atara Biotherapeutics Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Nov 06, 2018: Atara Biotherapeutics announces third quarter 2018 financial results and recent operational progress 43
Aug 01, 2018: Atara Biotherapeutics announces second quarter 2018 financial results and recent operational progress 45
May 08, 2018: Atara Biotherapeutics Announces First Quarter 2018 Financial Results and Recent Operational Progress 48
Feb 27, 2018: Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress 50
Nov 09, 2017: Atara Biotherapeutics Announces Third Quarter 2017 Financial Results and Recent Highlights 54
Aug 07, 2017: Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights 56
May 04, 2017: Atara Biotherapeutics Announces First Quarter 2017 Financial Results and Recent Highlights 58
Mar 09, 2017: Atara Bio Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights 60
Corporate Communications 61
Sep 11, 2018: Atara Biotherapeutics names Roy Baynes as Board Director 61
Jun 07, 2018: Atara Biotherapeutics Announces Appointment of Utpal Koppikar as Chief Financial Officer 62
May 07, 2018: Atara Biotherapeutics Appoints Dietmar Berger As Global Head Of Research And Development 63
Apr 09, 2018: Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 64
Feb 21, 2018: Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018 65
May 10, 2017: Atara Biotherapeutics appoints new SVP and global commercial head 66
Product News 67
09/11/2017: Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129 67
04/03/2017: Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer 68
Product Approvals 69
Jan 03, 2017: Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) 69
Clinical Trials 70
Jan 12, 2018: QIMR Berghofer-developed Immunotherapy for Multiple Sclerosis gets Green Light From US FDA to Proceed with Patient Enrollment at US sites for Global Phase 1 Clinical Study 70
Jan 02, 2018: Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 71
Dec 29, 2017: Atara Biotherapeutics Announces FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel In Patients With Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) 72
Dec 11, 2017: Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder 74
Nov 01, 2017: Atara Biotherapeutics Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results from a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus (EBV)-Associated Cancers 76
Oct 25, 2017: Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190 78
Oct 19, 2017: Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis 80
Oct 16, 2017: Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis 81
Aug 22, 2017: Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer 82
Jul 31, 2017: Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis 83
May 10, 2017: Atara Biotherapeutics Enhances Commercial Expertise with the Appointment of Dr. Derrell Porter to the Executive Leadership Team 84
Apr 20, 2017: Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis at the American Academy of Neurology Annual Meeting 2017 85
Mar 17, 2017: Atara Bio Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis 87
Mar 09, 2017: Atara Bio Provides Update on ATA-129 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Atara Biotherapeutics Raises US$52 Million In Series B Financing 12
Nina Biotherapeutics Raises US$0.9 Million In Venture Financing 14
Pinta Biotherapeutics Raises US$6.3 Million In Venture Financing 15
Santa Maria Biotherapeutics Raises US$6.3 Million In Venture Financing 16
Santa Maria Biotherapeutics Raises US$18 Million In Venture Financing 17
Pinta Biotherapeutics Raises US$18 Million In Venture Financing 18
Nina Biotherapeutics Raises US$2.5 Million In Venture Financing 19
Atara Biotherapeutics Secures USD1.01 Million in Venture Funding from Domain Associates 20
Atara Biotherapeutics and Moffitt Cancer Center Enter into Agreement 21
Atara Biotherapeutics Enters into Agreement with Merck 22
Atara Biotherapeutics Amends Licensing Agreement with QIMR Berghofer 23
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 24
Atara Biotherapeutics Enters into Licensing Agreement with Amgen 26
Atara Biotherapeutics Enters into Licensing Agreement with Amgen for AMG 745 27
Atara Biotherapeutics Raises USD172.5 Million in Public Offering of Shares 29
Atara Biotherapeutics Raises USD140 Million in Public Offering of Shares 31
Atara Biotherapeutics Raises USD207 Million in Public Offering of Shares 33
Atara Biotherapeutics Raises USD75 Million in Public Offering of Shares 35
Atara Biotherapeutics Raises USD63 Million in IPO 37
Atara Biotherapeutics Inc, Key Competitors 39
Atara Biotherapeutics Inc, Key Employees 40
Atara Biotherapeutics Inc, Other Locations 41
Atara Biotherapeutics Inc, Subsidiaries 41
List of Figures
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Atara Biotherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer